Rodin Therapeutics is discovering and developing first-in-class therapeutics for synaptopathies by applying novel chemical strategies to design molecules that safely upregulate genes crucial to learning and memory. Acquired by Alkermes in November 2019.
| Headquarters | Cambridge, MA |
| Website | www.rodintherapeutics.com |
| Pipeline | Phase 1 |
| @Rodintx |